this begin Thank phase appreciation call in you, thank for to everyone our by next growth call my ability for and Luis me company today. Board like in would of expressing the you conference my of Harmony forward to I confidence the joining Directors and this their story. lead to Harmony's
alongside who my a to be worked by of will phase, colleagues the whom executives this For talented I company. and this I common a share joined group management on next experienced build pharma goal have team, very
performance up who have the generated Biosciences talented want to-date. to also acknowledge I demonstrated have and incredibly thank the Harmony we group people of make and strong
seen of we have business, of to hear have me company's innovative care their After have the the treatments at can Harmony. practicing very was followed I how and Harmony am and in the journey every years eager beginning work say, by the total developing energized join aspect the by the As and delivering touching to-date. patients is made industry I neurologist, years they as it on we progress taking a patients, at XX impact I effort, XX that a families. of which team takes often
In fact, another we pitolisant. commercial quarter strong continued momentum business. report our saw excellence are and across of of pleased programs business well operational as to for our for We performance development an clinical WAKIX advancement in as our
unique profile commercial the strong organization. the of Our differentiated meaningfully a proven of excellence of since WAKIX product performance and result and the commercial launch is our
This WAKIX quarter, major and launches revenues for in launch, surpassing one for a we years within net company. rare disease the a most milestone achieved cumulative half ever since billion $X of the first three successful another
with are Many in our familiar founded investors was of on company analysts Harmony journey the XXXX. remarkable has the been and since
For story. our I those first who Harmony's this to highlights with milestones like of chapter from may some be you to share story, growth and would newer
that need narcolepsy. XXXX, closely accomplishments. for fast-track involved and the company XXXX, and breakthrough status some designation, the medical pitolisant fortunate many FDA's in in unmet Harmony's joining the have been granted therapy Since been were we an the at for leading I've and could with In start adult reflecting of to IND address important belief opened pitolisant patients
review. to expanded treatment adult provide the appropriate pitolisant time, then NDA under prepared was opened to while with narcolepsy, we access Around being and program with same an patients the
adult patients excessive WAKIX treatment or narcolepsy patients the pitolisant XXXX in who in with adult first patients this daytime still narcolepsy. treatment in for the EDS through commercial the sleepiness are compassionate of with use most of on for experienced significantly, program number approved WAKIX and And A today. FDA XXXX of cataplexy in
to The the of evidence, WAKIX, and in strong with demonstrated based body of FDA it was the scientific safe on which a with regulatory approval narcolepsy. around approvals be other world, along effective patients
In all clinical in conducted large development represents were over that approval drug an from clinical patients, orphan a X,XXX XX the based approval. database the during data on trials FDA fact, which program was for safety
was recently, age narcolepsy approval Most down our use Bioprojet patients partner for granted WAKIX to for EMA in pediatric six.
WAKIX of drivers in the interest healthcare fundamental and be business. Patient continue our to
XX% For year-over-year. we net revenue million, an increase reported the XXXX, WAKIX of quarter of first $XXX.X representing of
the will Growth on WAKIX, strong by for Jeffrey which continues later expand underlying demand the to be Dierks in driven call.
over a topline year. patient in three In of prescription years demand was strongest fact, for month of the the and WAKIX month new March highest in starts
the of which opportunity, WAKIX believe us WAKIX, and product with expect along market that the the profile growth continued we remains vast come. ability XXXX, of remainder provides grow differentiated For to for for narcolepsy, with a to years in WAKIX
WAKIX an additional in confident to hypersomnia with idiopathic in if being a plus current management up contribute to lifecycle are and billion We $X programs. billion narcolepsy potential the other potential approved $X opportunity
As you remains advancement build before, growth programs to out pipeline to our our lifecycle focus and with additional the current new of say for on growth. a drive assets heard management pitolisant me Harmony story acquisition of
lifecycle me later progress management extremely let will of the call, our I during highlights in more progress. some these have details share update the our clinical but are We with made pleased across programs. all on the we of provide current
of idiopathic III strong topline now months data accelerated we In this we led or hypersomnia an and the enrollment which momentum continue in to in about INTUNE in of fourth study, anticipate six timeline Phase IH, ahead our plan. see quarter patient year to
of or late end and results III study for to with quarter Syndrome from our Phase II Phase scheduled proposed PWS. patients trial PWS, proof-of-concept second FDA for III the discuss an meeting preparing with the Prader-Willi a in Phase we In are
populations. these advancing programs medical for these that additional lead development could unmet We our are indications are and to to in and new committed hopeful address pitolisant needs efforts patient
partner goal to management pitolisant, programs pitolisant franchise on formulations the for lifecycle beyond out we Bioprojet continue our with the progress make to In current XXXX. with to extend addition our new
It Another our our pipeline expand portfolio and next assets neurology acquiring rare business is beyond in development intent and expertise of of broad orphan phase our our where to diseases build we can key of other is leverage a WAKIX. new assets to component our out through existing neurological growth assets infrastructure.
across to both To quarter late we development and first $XXX after during financial the achieve range this, intend stages acquire end cash our securities cash, the of both additional and leverage position approximately early equivalents, with at launch stage the potential lifecycle. of strong to in the million WAKIX with assets and a to investment
am to of confidence the Board the lead this honored have organization Harmony to of my in and support of phase the conclude I next To remarks, growth. being opening forward
has made and to of extremely growth forward we I'm I look neurological people our that diseases. the proud as our rare to-date with team even help continued progress living more
turn Officer to Chief our our Commercial Jeffrey Jeff? provide performance. I commercial call will over details Dierks, more now to on the
